HUTCHMED Highlights HMPL-A830 Pre-Clinical Data Presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
— A novel EGFR-directed ATTC with a potent pan-KRAS payload designed to overcome resistance and systemic toxicity associated with EGFR/KRAS inhibition —